selected publications
-
Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study.
Clinical imaging.
2020
Academic Article
GET IT
Times cited: 3 -
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Gynecologic oncology.
2020
Academic Article
GET IT
Times cited: 16 -
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Gynecologic oncology.
2020
Academic Article
GET IT
Times cited: 2 -
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 41 -
Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience.
Research and practice in thrombosis and haemostasis.
2019
Academic Article
GET IT
Times cited: 20 -
Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
Gynecologic oncology.
2019
Academic Article
GET IT
Times cited: 18 -
Causes of Avascular Hypoechoic Testicular Lesions Detected at Scrotal Ultrasound: Can They Be Considered Benign?.
AJR. American journal of roentgenology.
2017
Academic Article
GET IT
Times cited: 12 -
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
Gynecologic oncology.
2017
Academic Article
GET IT
Times cited: 87 -
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.
Journal of thrombosis and thrombolysis.
2017
Academic Article
GET IT
Times cited: 82 -
Is It Time to Centralize Ovarian Cancer Care in the United States?.
Annals of surgical oncology.
2015
Review
GET IT
Times cited: 43 -
Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance.
American journal of obstetrics and gynecology.
2015
Academic Article
GET IT
Times cited: 9 -
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.
Gynecologic oncology.
2014
Academic Article
GET IT
Times cited: 162 -
Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy.
Radiology.
2013
Academic Article
GET IT
Times cited: 66 -
Implementation of evidence-based guidelines for thyroid nodule biopsy: a model for establishment of practice standards.
AJR. American journal of roentgenology.
2011
Academic Article
GET IT
Times cited: 46 -
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 25 -
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2010
Academic Article
GET IT
Times cited: 17 -
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 43 -
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 166 -
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
British journal of haematology.
2009
Academic Article
GET IT
Times cited: 49 -
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
British journal of haematology.
2009
Academic Article
GET IT
Times cited: 68 -
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 79 -
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 53 -
Limitations of CT during PET/CT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2007
Academic Article
GET IT
Times cited: 35 -
Prognostic nomogram for renal insufficiency after radical or partial nephrectomy.
The Journal of urology.
2006
Academic Article
GET IT
Times cited: 83